Findings

What do systematic reviews say?

1,490 questions · 1,526 findings · 124 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 263 · 17.2%GRADE not reported 224 · 14.7%Very low 292 · 19.1%Low 327 · 21.4%Moderate 286 · 18.7%High 134 · 8.8%

Quinine vs a quinine‐vitamin E combination (Q‐Vel)

Major adverse events · patients with muscle cramps

1 finding from 1 review

Quinine for muscle cramps 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 510 participants
Moderate

Quinine vs a quinine‐vitamin E combination (Q‐Vel)

Minor adverse events · patients with muscle cramps

1 finding from 1 review

Quinine for muscle cramps 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 510 participants
Moderate

Quinine vs a quinine‐vitamin E combination (Q‐Vel)

Number of cramps over 2 weeks · patients with muscle cramps

1 finding from 1 review

Quinine for muscle cramps 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 486 participants
Low

Single vs combination IV antibiotics

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 265 participants
Low

Single vs combination IV antibiotics

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 146 participants
Low

Single vs combination IV antibiotics

Time to next exacerbation · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Single vs combination IV antibiotics

Quality of life · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Non‐platinum single‐agent vs non‐platinum combination treatment

Overall survival (OS) · non‐small cell lung cancer in the elderly population

Non‐platinum single‐agent may leads to lower overall survival (OS) compared with non‐platinum combination treatment (low certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
HR 0.92
5 studies · 1294 participants
Low

Non‐platinum therapies vs platinum combination

1‐Year survival rate · non‐small cell lung cancer in the elderly population

Non‐platinum therapies probably leads to lower 1‐Year survival rate compared with platinum combination (moderate certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
RR 0.89
13 studies · 813 participants
Moderate

Non‐platinum therapies vs platinum combination

Progression‐free survival · non‐small cell lung cancer in the elderly population

Non‐platinum therapies may leads to lower progression‐free survival compared with platinum combination (low certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
HR 0.76
9 studies · 9 participants
Low

Non‐platinum therapies vs platinum combination

Objective response rate · non‐small cell lung cancer in the elderly population

Non‐platinum therapies probably leads to higher objective response rate (ORR) compared with platinum combination (moderate certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
RR 1.57
11 studies · 1432 participants
Moderate

Non‐platinum therapies vs platinum combination

Grade 3 or higher hematological toxicity for platinum therapies ‐ anemia · non‐small cell lung cancer in the elderly population

Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
RR 2.53
11 studies · 1437 participants
Low

Non‐platinum therapies vs platinum combination

Grade 3 or higher hematological toxicity for platinum therapies ‐ thrombocytopenia · non‐small cell lung cancer in the elderly population

Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
RR 3.59
9 studies · 1260 participants
Low

Non‐platinum therapies vs platinum combination

Grade 3 or higher Non‐Hematological Toxicity for Platinum‐based therapies ‐ Peripheral neuropathy · non‐small cell lung cancer in the elderly population

Non‐platinum therapies may leads to higher grade 3 or higher Non‐Hematological Toxicity for Platinum‐based… compared with platinum combination (low certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
RR 7.02
5 studies · 776 participants
Low

Non‐platinum therapies vs platinum combination

QoL · non‐small cell lung cancer in the elderly population

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 5 participants
GRADE not reported

Non‐platinum single‐agent vs non‐platinum combination treatment

1‐Year survival rate (OS1y) · non‐small cell lung cancer in the elderly population

Non‐platinum single‐agent may leads to lower 1‐Year survival rate (OS1y) compared with non‐platinum combination treatment (low certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
RR 0.88
4 studies · 993 participants
Low

Non‐platinum single‐agent vs non‐platinum combination treatment

Progression‐free survival · non‐small cell lung cancer in the elderly population

Non‐platinum single‐agent may leads to lower progression‐free survival compared with non‐platinum combination treatment (low certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
HR 0.94
4 studies · 1105 participants
Low

Non‐platinum single‐agent vs non‐platinum combination treatment

Objective response rate · non‐small cell lung cancer in the elderly population

Non‐platinum single‐agent may leads to higher objective response rate (ORR) compared with non‐platinum combination treatment (low certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
RR 1.79
5 studies · 1014 participants
Low

Non‐platinum single‐agent vs non‐platinum combination treatment

Grade 3 and 4 hematological adverse events (AE) ‐ anemia · non‐small cell lung cancer in the elderly population

It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ anemia compared with non‐platinum combination treatment (very low certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
RR 1.18
4 studies · 983 participants
Very low

Non‐platinum single‐agent vs non‐platinum combination treatment

Grade 3 to 4 neutropenia · non‐small cell lung cancer in the elderly population

Non‐platinum single‐agent may leads to higher grade 3 and 4 hematological adverse events (AE) ‐ neutropenia compared with non‐platinum combination treatment (low certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
RR 1.19
5 studies · 1064 participants
Low